Disease relevance of NAPROXEN

• We describe a patient receiving long-term naproxen (Naprosyn) therapy in whom unilateral spontaneous adrenal hemorrhage developed [1].
• Assessment of the efficacy of a nonsteroidal anti-inflammatory drug, Naprosyn, in the treatment of gingivitis [2].
• 26 women aged 15-45 with severe, primary dysmenorrhea were treated with naproxen (NAPROSYN, SYNTEX) and placebo during 2 x 2 consecutive menstrual cycles in a randomized, double-blind crossover study [3].
• Altogether 105 rheumatic patients, 35 in each of three groups, took part in a double-blind parallel study comparing naproxen (Naprosyn, Syntex) 500 mg suppositories with oxyphenbutazone (Tanderil, Geigy) 250 mg suppositories and placebo in postoperative pain and swelling after joint surgery [4].
• A comparison of Naprelan and Naprosyn in the treatment of osteoarthritis of the knee [5].

High impact information on NAPROXEN

• Synthesis and in vitro evaluation of novel morpholinyl- and methylpiperazinylacyloxyalkyl prodrugs of 2-(6-methoxy-2-naphthyl)propionic acid (Naproxen) for topical drug delivery [6].
• We conclude that conjugation of Nap to HSA itself results in a selective delivery to endothelial cells and that the local proteolysis of the conjugate produces an active catabolite [7].
• Coupling of Nap to Lact27-HSA and Man10-HSA resulted in a major shift in intrahepatic distribution from endothelial cells to the hepatocytes and Kupffer cells, respectively [7].
• Naproxen (Naprosyn). Pharmacokinetics: therapeutical relevance and tolerance profile [8].
• A comparative study of Butacote and Naprosyn in ankylosing spondylitis [9].

Anatomical context of NAPROXEN

• Each of three separate PG synthetase inhibitors introduced into the co-cultures-indomethacin 28 microM, 5, 8, 11, 14-eicosatetraynoic acid (ETYA) 33 microM, or Naprosyn 217 microM--decreased the suppression of the maternal T cells by a maximum of 65%, indicating the importance of PG for the suppression [10].
• The effect of paracetamol against ulcerogenic agent, naprosyn on the gastric mucosa of albino rat was observed under dissecting as well as laboratory microscope [11].
• To remove the retained pulpal components and residual NA, the pulp chamber of each disc was washed out with PBS and placed in an ultrasonic cleaner [12].
• Under laboratory microscope, a significant increase in the mucosal thickness with the administration of paracetamol followed by naprosyn was observed, while the flattening of the surface epithelium with slight exfoliation may be attributed to relative increase of pepsin from the chief cell [11].
• In the duodenum, there was a significant difference in favor of Naprelan over Naprosyn (P = 0.0236), and in favor of Naprelan over aspirin (P = 0.0086), but the difference between Naprosyn and aspirin was not significant (P = 0.6643) [13].

Associations of NAPROXEN with other chemical compounds

• The survival rate over 2 years ranged from 63% (N) to 75% (Indo) [14].
• Internal pH measurements by EPR revealed that the micro-pH inside 100% EA and 50/50 EA/N matrices were lower than 50/50 EA/NS matrices and in all cases lower than the penetrating buffer pH [15].
• The effect of paracetamol on naprosyn induced damage to gastric mucosa in albino rat [11].
• In a 12-week double-blind controlled trial diflunisal was compared with naproxen (Naprosyn; Syntex) in patients with rheumatoid arthritis [16].
• The excretion rates of SA and NA were both much lower than their filtration rate, indicating extensive reabsorption [17].

Gene context of NAPROXEN

• Synthesis and cyclooxygenase inhibitory properties of novel (+) 2-(6-methoxy-2-naphthyl)propanoic acid (naproxene) derivatives [18].
• Naproxen (Naprosyn) and the new non-steroidal anti-inflammatory drugs in rheumatoid arthritis [19].
• The drug diffusion of SS was significantly higher than MN and NA (one-way anova, P < 0.05), independent of iontophoresis [20].
• NSAIDs with still high percutaneous activities are ketoprofen (CAS 22071-15-4), naproxen (CAS 22204-53-1), piroxicam (CAS 36322-90-4) and diclofenac (CAS 15307-86-5) [21].

Analytical, diagnostic and therapeutic context of NAPROXEN

• After treatment, the mean headache frequency decreased to 4.1 per month (range, 0 to 12), a decrease of 62.4% (n = 54) [22].
• Our results of the morphological and histochemical studies in rats support the clinical observations of mucosal destruction in stomach in patients after oral administration of Naprosyn [23].
• We conclude the Naprosyn test remains a valuable diagnostic test to use to narrow differential diagnostic possibilities in patients with FUOs when a malignancy is a diagnostic consideration [24].

References